Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.82 |
| ▸ | HTT | P42858 | 3/20 | 0.82 |
| ▸ | HPGD | P15428 | 3/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.82 |
| ▸ | PKM | P14618 | 2/20 | 0.82 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.82 |
| ▸ | TSHR | P16473 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.74 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13576495 | 0.89 | KMT2A (0.82) | MAPTHTTHPGDHSD17B10MAPK1 | |
| SCHEMBL30657206 | 0.87 | MEN1 (1.00) | MAPTHTTHPGDHSD17B10MAPK1 | |
| SCHEMBL6315596 | 0.87 | MEN1 (1.00) | MAPTHTTHPGDHSD17B10MAPK1 | |
| SCHEMBL333699 | 0.86 | MAPT (0.61) | MAPTHTTHPGDHSD17B10MAPK1 | |
| SCHEMBL27699005 | 0.85 | MAPT (0.81) | MAPTHTTHPGDHSD17B10MAPK1 | |
| SCHEMBL981022 | 0.85 | TP53 (0.65) | MAPTHTTHPGDHSD17B10MAPK1 | |
| SCHEMBL29059266 | 0.85 | KMT2A (0.75) | MAPTHTTHPGDHSD17B10MAPK1 | |
| SCHEMBL29059242 | 0.83 | MEN1 (0.63) | MAPTHTTHPGDHSD17B10MAPK1 | |
| SCHEMBL28809867 | 0.83 | MEN1 (0.68) | MAPTHTTHPGDHSD17B10MAPK1 | |
| SCHEMBL30657205 | 0.83 | MEN1 (0.68) | MAPTHTTHPGDHSD17B10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-1771169-A1 | METHODS FOR TREATING HEPATITIS C | PTC Therapeutics, Inc. (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20060223863-A1 | Methods for treating Hepatitis C | KARP GARY M | 2006-10-05 | — | — | US | disclosed |
| US-20060189606-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2006-08-24 | — | — | US | disclosed |
| WO-2006019831-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299068-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | MAPT 4477/4885HTT 3147/4885HPGD 3255/4885 |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, LIPC, HCCS | MAPT 3547/4885HTT 4087/4885HPGD 1342/4885 |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | MAPT 4416/4885HTT 3355/4885HPGD 1033/4885 |
| US-20060189606-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | MAPT 4477/4885HTT 3147/4885HPGD 3255/4885 |
| US-20070299069-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | MAPT 4477/4885HTT 3147/4885HPGD 3255/4885 |
| US-20060223863-A1 | Methods for treating Hepatitis C | OAT, HAVCR2, HCCS | MAPT 4416/4885HTT 3355/4885HPGD 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.